Results 121 to 130 of about 325,417 (262)
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Correction: A sustainability framework based on threats, consequences, and solutions (TCS) for managing watershed commons. [PDF]
Camarillo ALQ, Randhir TO.
europepmc +1 more source
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant +7 more
wiley +1 more source
A Proxy Method to Bridge LCA Data Gaps Using Automated Material Classification and Probabilistic Under-Specification. [PDF]
Ellingboe E +3 more
europepmc +1 more source
A generalist institutional data repository offering both open and restricted access to support NIH data sharing compliance. [PDF]
Kim S, Jian X, Vana ML.
europepmc +1 more source
Cold stress during winter over North India: Patterns, trends, and mortality risks. [PDF]
Athira KS, Attada R, Komeravelli S.
europepmc +1 more source
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche +10 more
wiley +1 more source
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi +6 more
wiley +1 more source

